The abnormal deposition of modified Tau is the pathognomonic hallmark of many neurodegenerative diseases called “tauopathies”, including but not limited to Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), and chronic traumatic encephalopathy (CTE) (Lee et al., 2001; Arendt et al., 2016). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.